Orthobiologics are the wrong treatment when the outcome you are hoping for is not the outcome the biology is likely to produce. Most often that means you are expecting structural repair of cartilage, while the realistic effect is on symptoms and function. In a cross-sectional survey of 357 orthopaedic patients at a single United States academic medical center, published in the Orthopaedic Journal of Sports Medicine in 2026, 66.9% believed orthobiologics could treat cartilage injuries — which is precisely the mismatch that has to be resolved before anyone books a procedure.
What “not the right treatment” actually means
It usually means the goal, the mechanism, and your specific clinical picture do not line up. It is a different statement from “orthobiologics do not work,” and a different statement again from “orthobiologics are wrong for you permanently.”
We separate those three. Most decisions here are conservative-first, then adjusted when conservative measures have not reached the target, and a treatment that does not fit today can fit later once the target is clearer.
When the expectation is cartilage repair but the achievable goal is pain control
This is the most common mismatch we see. In the 2026 survey of those 357 patients, cartilage injury was the second most frequently selected condition patients believed orthobiologics could manage, behind pain and inflammation, which were selected by 70.9%.
In clinic that shows up as frustration after a prior PRP injection, or disappointment that follow-up imaging looks unchanged. Our job is to connect what you are hoping for with what is likely to happen in the tissue, and then to pick a next step you can actually live with.
Setting the target before discussing any product
We start by defining what success means to you in concrete terms — pain during a specific activity, morning stiffness, swelling, or getting back a particular movement. Only then do we confirm which tissue problem we are trying to address.
That is why a bone-on-bone knee conversation does not begin with a list of injections. It begins with the clinical picture, and with an honest account of what biology and time will allow.
When the mechanism you want is not the mechanism that operates
Even when a biologic is delivered correctly, the regenerative mechanism patients have in mind is often not the one doing the work. Writing about cell-based orthobiologic therapies in Clinics in Sports Medicine in 2025, Sachs and colleagues state that it is likely these mechanisms are not actively occurring nor leading to tissue regeneration in most clinical settings where these agents are used today.
The same authors describe the prospects for true regeneration from so-called mesenchymal stem cells as largely aspirational at this juncture, and characterize the impact of these cell-based therapies as predominantly symptom modifying rather than disease modifying or structure modifying with true tissue regeneration.
Symptom modification is not structure change
If your plan is built around cartilage repair, the risk is that the outcome you want is not the outcome the treatment is most likely to deliver. That is a reason to change the plan, not a reason to quietly proceed and hope.
We still consider orthobiologics where they fit — as a bridge, or as one component of a broader plan. In advanced knee osteoarthritis specifically, we frame PRP the way the trial authors framed it: a safe bridge therapy prior to arthroplasty. We do not present a single injection as a structural solution when the reasoning is thinner than the expectation.
When imaging and symptoms do not point at the same target
It is entirely possible to have degenerative findings on a scan while the pain is being driven by something else — soft tissue irritation, load distribution, or systemic metabolic inflammation. The reverse happens too: significant symptoms with no single obvious target on imaging.
When symptoms and therapeutic target do not align, injection decisions drift into trial and error. We try to close that gap with a terrain-first evaluation before anything is injected.
Terrain-first evaluation can change the direction entirely
Our terrain focus looks at the metabolic and systemic factors that influence tissue healing and joint behavior. When we find modifiable contributors, orthobiologics may still belong in the plan — but they stop being the whole plan, and their timing usually changes.
When timing and cost make it the wrong moment
Even a reasonable candidate procedure can be the wrong choice this month. Sachs and colleagues report that despite the rapid growth in orthobiologic use, there is sparse literature on the economic landscape and limited cost transparency across the country, and that a survey of physicians providing regenerative medicine procedures showed significant variability in patient costs with no analysis linking cost to outcome.
That environment makes it hard for a patient to compare options on value. If you cannot follow an injection with the rehabilitation and follow-up it depends on, the injection is not the right next step yet.
How we handle this
We do not publish a single figure for a procedure, because what a plan involves varies with the findings. What we do is discuss the specifics with you directly during evaluation, so the decision is made on information rather than on uncertainty.
When a knee replacement conversation should not be deflected
Many patients arrive wanting to avoid knee replacement, and we take that seriously. We also keep it honest, because an alternative that is not working is not an alternative — it is a delay.
Bone marrow aspirate concentrate and Lipogems come up in the same way. We weigh them against your tissue target, your prior treatments, and your terrain, rather than treating them as automatic substitutes for a decision that has already become necessary. Conservative measures come first, and when they have genuinely been exhausted, surgery is a legitimate step — one this practice provides, since Dr. Gurpreet Singh Padda, MD, MBA, MHP is a surgeon.
When the pain generator is somewhere else
Intradiscal orthobiologics may be relevant for some spinal diagnoses and irrelevant for others, and the deciding factor is where the pain is actually generated, not which procedure is available. The same logic applies when peptide medicine comes up: it is a clinical and educational subject here, aligned to your evaluation, and it does not substitute for identifying the source of the problem.
What we do instead when orthobiologics do not fit
We revise the plan rather than leaving you with a decline. Usually that means changing the target or the sequence — addressing systemic contributors first, or using a modality that matches the problem better than an injection would.
Regen.MD is at 4477 Woodson Rd, Suite 103, St. Louis, MO 63134, next to St. Louis Lambert International Airport; directions are on our St. Louis clinic page. The full range of procedures we do perform is listed on our orthobiologics services page.
Find out what is actually driving your pain
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call (314) 295-3000 or text (314) 886-5902.
Frequently Asked Questions
How do I know whether orthobiologics are wrong for my knee pain?
The test is whether your pain pattern and tissue target match what the treatment can plausibly do; if your stated goal is cartilage repair or structural change, that is where the evidence is weakest and where we would recommend against proceeding on those terms. How we run that assessment is described in our approach to clinical evaluation.
My MRI says “cartilage damage” — is PRP worth trying?
That decision is not made on MRI wording alone, and it is worth knowing that in the 2026 survey of 357 orthopaedic patients, two-thirds believed orthobiologics could treat cartilage injuries — an expectation the cited evidence does not support. Background on how we read imaging against symptoms is in the Regen.MD library.
What are intraosseous and subchondral PRP, and when are they the wrong choice?
Both place the injection in a specific bone-adjacent region of the joint based on a clinical hypothesis about where the pain is generated, so they are the wrong choice when the pain generator is elsewhere or when the stated goal is structural regeneration. The delivery targets are described on our orthobiologics services page.
Can BMAC replace surgery for a bone-on-bone knee?
It should not be presented that way — the cited 2025 analysis describes cell-based therapies as predominantly symptom modifying rather than structure modifying, and in advanced knee osteoarthritis PRP is framed as a bridge prior to arthroplasty. Where surgery is genuinely the right step it is available here, and the conditions we evaluate along that pathway are listed on our conditions page.
Should I consider peptide medicine instead of an injection?
Not as a swap. If the dominant contributor looks systemic and metabolic rather than a local cartilage or tendon target, a different plan may fit better, and peptides are discussed here as a clinical and educational subject rather than as a substitute procedure — the framing is on our peptide therapy page.
Sources
- Garcia JR, Pallone LV, Gilat R, et al., “What Do Patients Know About Orthobiologics? Perceived Efficacy, Safety, and Factors Influencing Treatment Decisions,” Orthopaedic Journal of Sports Medicine, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12929896/ — cross-sectional survey of 357 eligible respondents at Rush University Medical Center, October 2023 to April 2024. Referenced for the finding that pain and inflammation were most frequently selected (n = 253; 70.9%), followed by cartilage injuries (n = 239; 66.9%).
- Sachs JP, Mufti YN, Bi AS, Cole BJ, “Economic Realities of Orthobiologics,” Clinics in Sports Medicine, 2025;44(4):827–840, https://doi.org/10.1016/j.csm.2024.10.011 — referenced for the statements that the regenerative mechanisms of cell-based orthobiologics are likely not actively occurring nor leading to tissue regeneration in most clinical settings, that true regeneration from mesenchymal stem cells is largely aspirational at this juncture, that their impact is predominantly symptom modifying rather than disease or structure modifying, and that there is sparse literature on the economic landscape with limited cost transparency and significant variability in patient costs.